VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
GNFTGenfit S.A.
$8.95$448M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksGNFTP/E History

GNFT logoGenfit S.A. (GNFT) P/E Ratio History

Expensive

Trading at 256.9x vs 5Y avg 6.7x · 100th percentile · Material premium to history · Data 2022–2023

Current P/E (TTM)
256.9x
+3715% vs 5Y avg
5Y Avg P/E
6.7x
Median 9.1x
5Y Percentile
100th
Upper end of range
PEG Ratio
N/A
5-Year P/E Range
256.9x
Min4.4xMedian9.1xMax9.1x
TTM EPS$-0.33
Price$8.95
Earnings Yield0.39%
EPS Growth (1Y)105.2%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Genfit S.A. (GNFT) trades at a price-to-earnings ratio of 256.9x, with a stock price of $8.95 and trailing twelve-month earnings per share of $-0.33.

The current P/E is 3715% above its 5-year average of 6.7x. Over the past five years, GNFT's P/E has ranged from a low of 4.4x to a high of 9.1x, placing the current valuation at the 100th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, GNFT trades at a 1061% premium to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.

Relative to the broader market, GNFT commands a significant premium over the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GNFT DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GNFT Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
256.9vs22.1
+1061%
Above Sector
vs. S&P 500
256.9vs24.3
+956%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 105% EPS growth (1Y)

GNFT P/E vs Peers

Metabolic and Obesity Therapies peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
HALO logoHALOHalozyme Therapeutics, Inc.
$8B26.9Lowest1.17Best-25%
ALNY logoALNYAlnylam Pharmaceuticals, Inc.
$38B122.9-+207%Best
LLY logoLLYEli Lilly and Company
$1.0T48.11.66+96%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

GNFT Historical P/E Data (2022–2023)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2023 Q2Jun 30 2023$3.54$0.399.1x+35%
FY2022 Q4Dec 31 2022$4.39$1.004.4x-35%

Average P/E for displayed period: 6.7x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

4+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GNFT — Frequently Asked Questions

Quick answers to the most common questions about buying GNFT stock.

What is GNFT's P/E ratio?

Genfit S.A. (GNFT) trailing twelve-month P/E ratio is 256.9x, based on TTM diluted EPS of $-0.33. The 5-year average P/E is 6.7x and the historical range spans 4.4x to 9.1x.

Is GNFT stock overvalued or undervalued?

GNFT trades at 256.9x P/E, above its 5-year average of 6.7x. The 100th percentile ranking within the 4.4x–9.1x historical range indicates a premium to historical valuation.

Is GNFT stock expensive?

Yes, GNFT is expensive relative to its own history. The current P/E of 256.9x is above the 5-year average of 6.7x and also above the Healthcare sector median of 22.1x. The stock sits at the 100th percentile of its 5-year valuation range.

What is GNFT's historical P/E range?

Over the past 5 years, GNFT's P/E ratio has ranged from 4.4x to 9.1x, with a median of 9.1x and an average of 6.7x. The current P/E of 256.9x places the stock at the 100th percentile of this range. Full historical data spans 2022–2023.

How does GNFT's P/E compare to the S&P 500?

GNFT trades at 256.9x P/E versus the S&P 500 median of 24.3x. The 957% premium to the market typically reflects higher expected earnings growth or quality.

How does GNFT's valuation compare to Healthcare peers?

Genfit S.A. P/E of 256.9x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is GNFT's PEG ratio?

GNFT PEG ratio is N/A, based on a P/E of 256.9x and EPS growth of 105.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is GNFT's earnings yield?

GNFT earnings yield is 0.39%, the inverse of its 256.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

GNFT P/E Ratio History (2022–2023)

Quarterly valuation multiple from closing price and trailing EPS

Current9.1x
Period Avg6.7x
Range4.4x - 9.1x
Change+107%
2 quartersDec 31, 2022 - Jun 30, 2023